articleThe LancetSep 1, 2020BRONZE OA

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

DYDenis Y. LogunovIVInna V. DolzhikovaOVOlga V. ZubkovaAIAmir I. TukhvatulinDVDmitry V. Shcheblyakov

Ministry of Health of the Russian Federation · Sechenov University · +2 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,118
total citations
FWCI
175.61
Percentile
100%
References
32
Citations per year

Authors

32

Topics & keywords

Topics
Keywords
  • Immunogenicity
  • Coronavirus disease 2019 (COVID-19)
  • Virology
  • 2019-20 coronavirus outbreak
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Medicine
  • Heterologous
  • Prime (order theory)
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding